NCT00985153View on ClinicalTrials.gov

Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)

PHASE3CompletedINTERVENTIONAL
Enrollment

3,927

Participants

Timeline

Start Date

March 31, 2000

Primary Completion Date

May 31, 2001

Study Completion Date

May 31, 2001

Conditions
MeaslesMumpsRubellaVaricella
Interventions
BIOLOGICAL

Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live

A Single 0.5 mL subcutaneous injection at Day 0

BIOLOGICAL

Comparator: Varivax

A Single 0.5 mL subcutaneous injection at Day 0

BIOLOGICAL

Comparator: M-M-R II

A Single 0.5 mL subcutaneous injection at Day 0

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00985153 - Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED) | Biotech Hunter | Biotech Hunter